StockData

Alnylam Pharmaceuticals vs Regeneron Pharmaceuticals

ALNY and REGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and REGN compare

Regeneron Pharmaceuticals is the larger company, worth 4.6 times as much as Alnylam Pharmaceuticals ($98.5B against $21.4B).

On earnings, Alnylam Pharmaceuticals is cheaper: it trades at 8.3× trailing earnings, against 21.0× for Regeneron Pharmaceuticals.

Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus 18.6% for Regeneron Pharmaceuticals).

Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with 28.5% at Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals pays a dividend yielding 0.39%; Alnylam Pharmaceuticals does not pay one.

Regeneron Pharmaceuticals scores higher on the StockData Score (16 against 10 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYREGN
Size and price
Market cap$21.4B$98.5B
Share price$159.73$952.40
Change, 1 year−64.8%37.0%
Change, 5 years−15.3%48.0%
Beta (5Y)0.900.16
Employees2,50015K
StockData Score
Total score1016 (better)
Valuation score3 (better)1
Growth score22
Performance score34 (better)
Health score26 (better)
Dividend score03 (better)
Valuation
P/E8.3× (better)21.0×
P/S4.3× (better)5.8×
P/B5.9×2.9× (better)
EV/EBITDA17.2×17.0× (better)
P/FCF26.5×25.7× (better)
PEG–7.61
FCF yield3.8%3.9% (better)
Fair value$298.86$862.07
Margin of safety46.6% (better)−10.5%
Growth
Revenue growth (TTM)56.2% (better)18.6%
Revenue growth, 5Y average49.8% (better)11.0%
Net income growth (TTM)2137% (better)5.2%
EPS growth (TTM)2308% (better)8.4%
EPS growth, 5Y average–6.3%
Profitability
Gross margin77.4%–
Operating margin19.5%28.8% (better)
Net margin52.8% (better)28.5%
FCF margin16.1%22.6% (better)
Return on equity127% (better)14.9%
Return on invested capital–16.3%
Financial health
Debt / equity–0.06
Net debt / EBITDA–−1.36
Interest coverage3.2×104× (better)
Current ratio2.483.35 (better)
Altman Z-score3.687.80 (better)
Piotroski F-score6 (better)5
Dividends and buybacks
Dividend yield–0.39%
Payout ratio–8.0%
Buyback yield–2.0%
Shareholder yield0.00%2.4% (better)
Ownership
Held by institutions99.7%88.5%
Held by insiders0.49%3.7%
Insider net buying, 12 months−$26.3M (better)−$57.4M
Superinvestors holding–1
Short interest, % of float4.1%2.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.